Format

Send to

Choose Destination
Recent Results Cancer Res. 2010;184:173-87. doi: 10.1007/978-3-642-01222-8_12.

Bortezomib.

Author information

1
Department of Internal Medicine II, University Hospital Würzburg, Josef-Schneider Strasse 2, Würzburg, 97080, Germany. Einsele_h@klinik.uni-wuerzburg.de

Abstract

The ubiquitin-mediated degradation of proteins in numerous cellular processes, such as turnover and quality control of proteins, cell cycle and apoptosis, transcription and cell signaling, immune response and antigen presentation, and inflammation and development makes the ubiquitin-proteosome systems a very interesting target for various therapeutic interventions. Proteosome inhibitors were first synthesized as tools to probe the function and specificity of this particle's proteolytic activities. Most synthetic inhibitors rely on a peptide base, which mimics a protein substrate, attached at a COOH terminal "warhead". Notable warheads include boronic acids, such as Bortezomib and epoxyketones, such as carfilzomib. A variety of natural products also inhibit the proteosome that are not peptide-based, most notably lactacystin, that is related to NPI-0052, or salinosporamide A, another inhibitor in clinical trials. The possibility that proteosome inhibitors could be drug candidates was considered after studies showed that they induced apoptosis in leukemic cell lines. The first proteasome inhibitor in clinical application, Bortezomib showed activity in non small cell lung and androgen-independent prostate carcinoma, as well as MM and mantle cell and follicular non-Hodgkin's lymphoma. It is now lincensed for the treatment of newly diagnosed as well as relapsed/progressive MM and has had a major impact on the improvement in the treatment of MM in the last few years.

PMID:
20072838
DOI:
10.1007/978-3-642-01222-8_12
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center